GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Cash Flow from Financing

Clover Biopharmaceuticals (HKSE:02197) Cash Flow from Financing : HK$-362.93 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2024, Clover Biopharmaceuticals received HK$0.01 Mil more from issuing new shares than it paid to buy back shares. It spent HK$101.93 Mil paying down its debt. It paid HK$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.00 Mil from paying cash dividends to shareholders. It spent HK$9.32 Mil on other financial activities. In all, Clover Biopharmaceuticals spent HK$111.24 Mil on financial activities for the six months ended in Jun. 2024.


Clover Biopharmaceuticals Cash Flow from Financing Historical Data

The historical data trend for Clover Biopharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Cash Flow from Financing Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial 375.60 3,743.41 539.53 -155.76 -

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 555.51 86.71 -242.48 -120.45 -

Clover Biopharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Clover Biopharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Clover Biopharmaceuticals's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-362.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clover Biopharmaceuticals  (HKSE:02197) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Clover Biopharmaceuticals's issuance of stock for the six months ended in Jun. 2024 was HK$0.01 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Clover Biopharmaceuticals's repurchase of stock for the six months ended in Jun. 2024 was HK$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Clover Biopharmaceuticals's net issuance of debt for the six months ended in Jun. 2024 was HK$-101.93 Mil. Clover Biopharmaceuticals spent HK$101.93 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Clover Biopharmaceuticals's net issuance of preferred for the six months ended in Jun. 2024 was HK$0.00 Mil. Clover Biopharmaceuticals paid HK$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Clover Biopharmaceuticals's cash flow for dividends for the six months ended in Jun. 2024 was HK$0.00 Mil. Clover Biopharmaceuticals received HK$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Clover Biopharmaceuticals's other financing for the six months ended in Jun. 2024 was HK$-9.32 Mil. Clover Biopharmaceuticals spent HK$9.32 Mil on other financial activities.


Clover Biopharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals Headlines

No Headlines